JP2016537366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537366A5 JP2016537366A5 JP2016531020A JP2016531020A JP2016537366A5 JP 2016537366 A5 JP2016537366 A5 JP 2016537366A5 JP 2016531020 A JP2016531020 A JP 2016531020A JP 2016531020 A JP2016531020 A JP 2016531020A JP 2016537366 A5 JP2016537366 A5 JP 2016537366A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- independently selected
- heterocyclyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC1(C)C2=C(C(N)=O)C(*)=**2C(*)(*)C(*)(*)*1C(**)=O Chemical compound CC1(C)C2=C(C(N)=O)C(*)=**2C(*)(*)C(*)(*)*1C(**)=O 0.000 description 21
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904116P | 2013-11-14 | 2013-11-14 | |
| US61/904,116 | 2013-11-14 | ||
| PCT/US2014/065599 WO2015073767A1 (en) | 2013-11-14 | 2014-11-14 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537366A JP2016537366A (ja) | 2016-12-01 |
| JP2016537366A5 true JP2016537366A5 (enExample) | 2017-12-21 |
| JP6494622B2 JP6494622B2 (ja) | 2019-04-03 |
Family
ID=51952052
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531020A Expired - Fee Related JP6494622B2 (ja) | 2013-11-14 | 2014-11-14 | カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体 |
| JP2016531646A Expired - Fee Related JP6494624B2 (ja) | 2013-11-14 | 2014-11-14 | カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531646A Expired - Fee Related JP6494624B2 (ja) | 2013-11-14 | 2014-11-14 | カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9598423B2 (enExample) |
| EP (2) | EP3068784B1 (enExample) |
| JP (2) | JP6494622B2 (enExample) |
| CN (2) | CN105916856B (enExample) |
| AR (1) | AR098414A1 (enExample) |
| ES (2) | ES2718218T3 (enExample) |
| TW (1) | TW201605859A (enExample) |
| UY (1) | UY35834A (enExample) |
| WO (2) | WO2015073763A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35834A (es) | 2013-11-14 | 2015-05-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon |
| WO2015129821A1 (ja) | 2014-02-27 | 2015-09-03 | 国立大学法人東京大学 | オートタキシン阻害活性を有する縮合ピラゾール誘導体 |
| MA41338B1 (fr) * | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| BR112018067964B1 (pt) | 2016-03-07 | 2024-01-16 | Enanta Pharmaceuticals, Inc | Composto, composição farmacêutica que o compreende e uso do referido composto |
| EP3426674A4 (en) | 2016-03-09 | 2019-08-14 | Blade Therapeutics, Inc. | CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| CN109153682B (zh) * | 2016-05-20 | 2021-05-25 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物 |
| WO2018009417A1 (en) | 2016-07-05 | 2018-01-11 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
| JP7051804B2 (ja) * | 2016-07-14 | 2022-04-11 | エフ．ホフマン－ラ ロシュ アーゲー | 感染症の治療のための６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物と６，７－ジヒドロ－４Ｈ－トリアゾロ［１，５－ａ］ピラジン化合物 |
| KR20190063473A (ko) * | 2016-09-28 | 2019-06-07 | 블레이드 테라퓨틱스, 인크. | 칼페인 조정자 및 그 치료학적 용도 |
| TWI782056B (zh) * | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| WO2019020070A1 (zh) * | 2017-07-27 | 2019-01-31 | 江苏恒瑞医药股份有限公司 | 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用 |
| IL272941B2 (en) | 2017-08-28 | 2023-03-01 | Enanta Pharm Inc | Antiviral agents for viral hepatitis b |
| TWI846350B (zh) | 2017-09-15 | 2024-06-21 | 美商佛瑪治療公司 | 作為ＣＢＰ／ｐ３００抑制劑之四氫－咪唑並喹啉化合物 |
| SG11202003827YA (en) | 2017-11-01 | 2020-05-28 | Bristol Myers Squibb Co | Bridged bicyclic compounds as farnesoid x receptor modulators |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2019191166A1 (en) * | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN111295380B (zh) * | 2018-06-01 | 2020-11-20 | 杭州阿诺生物医药科技有限公司 | 一种高活性csf1r抑制剂化合物 |
| MX2023013508A (es) | 2018-06-29 | 2023-12-13 | Forma Therapeutics Inc | Inhibicion de la proteina de union a creb (cbp). |
| WO2020061435A1 (en) | 2018-09-21 | 2020-03-26 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| KR102819704B1 (ko) | 2018-11-21 | 2025-06-11 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스제로서의 작용화된 헤테로사이클 |
| KR20210114001A (ko) | 2019-01-11 | 2021-09-17 | 시오노기 앤드 컴파니, 리미티드 | Mgat2 저해 활성을 갖는 다이하이드로피라졸로피라지논 유도체 |
| CN111484497B (zh) * | 2019-01-25 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法 |
| CN111484498B (zh) * | 2019-01-25 | 2021-05-14 | 江苏恒瑞医药股份有限公司 | 咪唑并[1,5-a]吡嗪类化合物的晶型及其制备方法 |
| TW202043233A (zh) * | 2019-01-25 | 2020-12-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 1,2,3-三氮唑并[1,5-a]吡類衍生物的晶型及其製備方法 |
| US12227501B2 (en) | 2019-02-07 | 2025-02-18 | Bayer Aktiengesellschaft | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors |
| US12351577B2 (en) | 2019-03-15 | 2025-07-08 | Forma Therapeutics, Inc. | Inhibiting cyclic AMP-responsive element-binding protein (CREB) |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| EP4188928B1 (en) | 2020-07-29 | 2024-07-24 | Bayer Aktiengesellschaft | Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof |
| CN114057745A (zh) * | 2020-07-29 | 2022-02-18 | 江苏恒瑞医药股份有限公司 | 一种三氮唑并[1,5-a]吡嗪制备方法及其应用 |
| US20230339970A1 (en) * | 2020-09-17 | 2023-10-26 | Janssen Pharmaceutica Nv | Casein kinase 1 delta modulators |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| TW202245772A (zh) * | 2021-02-04 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種衣殼蛋白抑制劑的醫藥組成物及其製備方法 |
| WO2023147015A1 (en) * | 2022-01-27 | 2023-08-03 | The Broad Institute, Inc. | Substituted heterocyclic csnk1 inhibitors |
| CA3257905A1 (en) * | 2022-06-13 | 2025-04-24 | Shionogi & Co., Ltd. | CRYSTAL OF A DIHYDROPYRIDINONE DERIVATIVE OR A SOLVATE THEREOF |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04002243A (es) * | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
| PT1747220E (pt) * | 2003-12-11 | 2009-07-08 | Aventis Pharma Inc | 1h-pirrolo[3,2-b, 3,2-c e 2,3-c]piridina-2-carboxamidas e análogos relacionados como inibidores da caseína-cinase i epsilon |
| US20050222171A1 (en) * | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| CN101417999A (zh) | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| EP2085398A1 (en) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| CN102223798A (zh) | 2008-09-24 | 2011-10-19 | 巴斯夫欧洲公司 | 用于防治无脊椎动物害虫的吡唑化合物 |
| WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
| TW201035102A (en) | 2009-03-04 | 2010-10-01 | Gruenethal Gmbh | Sulfonylated tetrahydroazolopyrazines and their use as medicinal products |
| FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| WO2012117048A1 (en) | 2011-03-02 | 2012-09-07 | Lead Discovery Center Gmbh | Pharmaceutically active disubstituted triazine derivatives |
| UY35834A (es) | 2013-11-14 | 2015-05-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon |
-
2014
- 2014-11-13 UY UY0001035834A patent/UY35834A/es unknown
- 2014-11-13 TW TW103139448A patent/TW201605859A/zh unknown
- 2014-11-13 AR ARP140104277A patent/AR098414A1/es unknown
- 2014-11-14 US US15/034,217 patent/US9598423B2/en active Active
- 2014-11-14 CN CN201480073199.9A patent/CN105916856B/zh not_active Expired - Fee Related
- 2014-11-14 US US14/541,343 patent/US9273058B2/en active Active
- 2014-11-14 ES ES14802796T patent/ES2718218T3/es active Active
- 2014-11-14 ES ES14806145T patent/ES2744636T3/es active Active
- 2014-11-14 EP EP14802796.4A patent/EP3068784B1/en not_active Not-in-force
- 2014-11-14 JP JP2016531020A patent/JP6494622B2/ja not_active Expired - Fee Related
- 2014-11-14 JP JP2016531646A patent/JP6494624B2/ja not_active Expired - Fee Related
- 2014-11-14 WO PCT/US2014/065594 patent/WO2015073763A1/en not_active Ceased
- 2014-11-14 EP EP14806145.0A patent/EP3068785B1/en not_active Not-in-force
- 2014-11-14 WO PCT/US2014/065599 patent/WO2015073767A1/en not_active Ceased
- 2014-11-14 CN CN201480073088.8A patent/CN105916855B/zh not_active Expired - Fee Related
-
2016
- 2016-01-13 US US14/994,346 patent/US20160122358A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016537366A5 (enExample) | ||
| JP2016537369A5 (enExample) | ||
| JP6474068B2 (ja) | ２−アミノピリミジン系化合物およびその薬物組成物と使用 | |
| JP2016507502A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2018522879A5 (enExample) | ||
| PH12019500930A1 (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| JP2015520140A5 (enExample) | ||
| JP2017518344A5 (enExample) | ||
| JP2018522866A5 (enExample) | ||
| JP2018516238A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| JP2016508135A5 (enExample) | ||
| JP2012532112A5 (enExample) | ||
| ME02838B (me) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| JP2013512903A5 (enExample) | ||
| JP2018522867A5 (enExample) | ||
| JP2014513139A5 (enExample) | ||
| RU2016134751A (ru) | Соединения | |
| JP2014506582A5 (enExample) | ||
| JP2016531868A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |